Among the patients, the Hb levels of ten patients increased by more than 10 g/L in 3 months, with the highest increase of 62 g/L, indicating that rHuEPO combined with Roxadustat was more effective than rHuEPO alone in the treatment of renal anemia in patients with hyperparathyroidism and that it can take effect within 3 months. This evidence concerns the gene GSTM1 and hyperparathyroidism.